Viruses represent one of the main factors that cause normal cells to proliferate and to become malignant: up to 15% of all human cancers are associated with single or multiple virus infections, and several viruses have been recognized as causal agents of specific types of cancer. Viruses have evolved many strategies to prevent infected cells from becoming apoptotic and to evade the innate and adaptive immune responses of their hosts. The recent discovery that Epstein-Barr virus and other herpesviruses produce their own sets of micro (mi)RNAs brings an additional layer of complexity in this ongoing host-virus arms race and changes our initial views of the antiviral roles of RNA silencing in plants and insects. It seems that, rather than being inhibited by this process, many mammalian viruses can usurp or divert the host RNA silencing machinery to their advantage. Viral-encoded miRNAs can act both in cis, to ensure accurate expression of viral genomes, and in trans, to modify the expression of host transcripts. Here, we review the current knowledge on viral miRNAs and discuss how mammalian viruses can also perturb host miRNA expression. Those recent findings provide new insights into the role of viruses and miRNAs in cancer development.
Viruses represent one of the main factors that cause normal cells to proliferate and to become malignant: up to 15% of all human cancers are associated with single or multiple virus infections, and several viruses have been recognized as causal agents of specific types of cancer. Viruses have evolved many strategies to prevent infected cells from becoming apoptotic and to evade the innate and adaptive immune responses of their hosts. The recent discovery that Epstein-Barr virus and other herpesviruses produce their own sets of micro (mi)RNAs brings an additional layer of complexity in this ongoing host-virus arms race and changes our initial views of the antiviral roles of RNA silencing in plants and insects. It seems that, rather than being inhibited by this process, many mammalian viruses can usurp or divert the host RNA silencing machinery to their advantage. Viral-encoded miRNAs can act both in cis, to ensure accurate expression of viral genomes, and in trans, to modify the expression of host transcripts. Here, we review the current knowledge on viral miRNAs and discuss how mammalian viruses can also perturb host miRNA expression. Those recent findings provide new insights into the role of viruses and miRNAs in cancer development. Oncogene (2006 Oncogene ( ) 25, 6211-6219. doi:10.1038 Keywords: virus; RNA silencing; microRNA; cancer; oncogene; cellular transformation Introduction: the intimacy between viruses and RNA silencing pathways Although micro (mi)RNAs are the central topic of this issue (we refer the reader to the contribution of G Hutvagner for details on miRNA biogenesis and modes of action), they represent only one type of RNA silencing effector molecules. Their identification was, in fact, preceded by the discovery of small interfering (si)RNAs, in silenced and virally infected plants (Hamilton and Baulcombe, 1999) . This breakthrough was not only instrumental for the development of the entire RNA silencing field, but it also directly validated the notion that RNA silencing is an antiviral defense system in plants, involving processing of viral doublestranded (ds)RNA by Dicer proteins. In the model plant Arabidopsis, DCL2 and DCL4 two of the four Dicer-like proteins act redundantly to promote antiviral defense upon incorporation of their respective siRNA product in an antiviral RISC that degrades viral transcripts (Deleris et al., 2006) . Virus-derived siRNAs have also been identified in insects and, in Drosophila, Dicer 2 and AGO2 act respectively as the Dicer and Slicer that are essential to protect this organism against viruses (Galiana-Arnoux et al., 2006; Wang et al., 2006) . Accordingly, the dcl2-dcl4 double mutant of Arabidopsis, as well as the ago2 and dicer2 mutants of Drosophila are hyper-susceptible to a broad range of viruses.
Further supporting a key role for RNA silencing in antiviral defense, plant and insect viruses commonly produce proteins that suppress various steps of the RNA silencing pathway (see Ding et al., 2004; Voinnet, 2005) . The significance of those viral suppressors of RNA silencing (VSRs) is illustrated by the fact that normal accumulation of Flock house virus that is deprived of the B2 VSR was rescued in Drosophila cells with compromised AGO2 functions (Galiana-Arnoux et al., 2006; Wang et al., 2006) . Similarly, high systemic accumulation and disease symptoms from a VSRdeficient virus were only observed in Arabidopsis mutants in which DCL2 and DCL4 were simultaneously inactivated (Deleris et al., 2006) . Although the genetics of plant and insect VSR function awaits characterization, many VSR exhibit strong in vitro and in vivo affinity for high-and/or low-molecular weight dsRNA, including siRNA and miR/miR* duplexes Merai et al., 2006) . Whether dsRNA binding is an inadvertent consequence of additional functions of VSRs requiring their close association with viral nucleic acids, or whether it represents a bona fide feature of silencing suppression remains, in most cases, unaddressed. Nonetheless, the 'siRNA caliper' P19 protein of plant tombusviruses provides an example of size-selective dsRNA binding that clearly forms the basis of VSR action in infection contexts (Vargason et al., 2003; Ye et al., 2003) .
In plants, viruses often, albeit not always, cause developmental symptoms that overlap with those of mutant plants deficient in miRNA biogenesis and function. Moreover, some of those developmental anomalies can be recapitulated by transgenic expression of individual VSRs, which, in most cases, appear to inhibit the slicer activity (AGO1) that accounts for miRNA-directed cleavage of target transcripts, the seemingly prevalent mode of action of plant miRNAs (Chapman et al., 2004; Dunoyer et al., 2004) . Therefore, the VSRs that are produced as a response to the hostsilencing defense are an important cause of misregulation of the plant miRNA pathway. It remains to be addressed whether this is also the case in insect-virus interactions.
In contrast to the situations in plants and invertebrates, there is, to date, no clear experimental data to support the idea that RNA silencing acts as an antiviral defense in differentiated cells of vertebrates, at least not in the ways described above. For instance, extensive cloning and sequencing of small RNAs from human cells infected with RNA viruses such as hepatitis C virus (HCV), yellow fever virus (YFV) or human immunodeficiency virus (HIV)1 did not provide any evidence for viral-derived siRNAs (Pfeffer et al., 2005) , whereas those molecules accumulate to large amounts in plant and insect infected tissues. Note that the lack of detectable siRNAs does not completely rule out their existence, notably in germline cells where retrotransposon-derived siRNAs have just been reported in mouse (Watanabe et al., 2006) . Nonetheless, it is currently thought that innate immune responses that are not sequence-specific in nature, most prominently the dsRNA-induced interferon (IFN) response, have largely perhaps totally supplanted the antiviral role of RNA silencing in differentiated vertebrate cells (Voinnet, 2005; Cullen, 2006 ). This idea is also supported by the fact that the diversification and specialization of Dicer proteins in antiviral defense, as seen in insects and plants (Deleris et al., 2006; Obbard et al., 2006) , is not a feature of the mammalian RNA silencing machinery, which is based on a single Dicer.
Several proteins with properties of VSR have been identified in mammalian-infecting viruses, such as vaccinia and influenza viruses . However, these findings should be interpreted cautiously because those proteins are known to bind to dsRNA to prevent activation of the protein kinase R (PKR), a major effector of the IFN response (Bergmann et al., 2000; Xiang et al., 2002) . Therefore, their inhibitory action on RNA silencing could merely represent a side effect of their primary IFN-antagonizing action. In addition, silencing suppression by those proteins was only studied in non-vertebrate systems, and, so, their role as authentic VSR in mammalian infections remains arguable .
Although a case can be made that mammalian viruses do not commonly produce siRNAs in contrast to their counterparts in insects and plants, the cloning/sequencing procedure described above led to the discovery, by several independent groups, that mammalian DNA viruses and in particular herpesviruses, encode their own sets of miRNAs. Viral miRNAs were first discovered in Epstein-Barr virus (EBV), (Pfeffer et al., 2004) , and have now been described in the case of Kaposi's sarcoma-associated herpesvirus (KSHV), human cytomegalovirus (HCMV), mouse gammaherpesvirus 68 (MHV68), herpes simplex virus 1 (HSV1) and simian virus 40 (SV40) (Cai et al., 2005; Pfeffer et al., 2005; Samols et al., 2005; Gupta et al., 2006) . The finding that viruses encode their own miRNAs was surprising but not totally unexpected given the extraordinary adaptation and mimicking capacities of viruses, and given the fact that the miRNA pathway is the prominent RNA silencing pathway that operates in differentiated mammalian cells. Although miRNA production probably represents one of the many strategies used by viruses to divert or usurp cellular machineries, it is striking that many of the miRNA-encoding viruses possess cellular transformation properties and have longstanding associations with cancer. We will review here what is known about viral miRNAs, and extrapolate how the action of those riboregulators can fit into the general schemes leading from viral infection to tumors. We will also elaborate on how virus infections in general might interact with, or perturb existing miRNA repertoires in mammalian cells, and might, thereby, promote cancer.
Origin and genomics of viral miRNAs
To date, all known viral miRNAs (listed in Table 1 ) have been identified in DNA viruses belonging to the Herpesviridae family, with the exception of the polyomavirus SV40. Computer predictions do not favor the existence of miRNAs in viruses with an RNA genome, which is supported by cloning data obtained with HCV and YFV. More generally, given the required nuclear processing of pre-miRNAs by Drosha (Lee et al., 2003) , it is very unlikely that cytoplasmic-restricted viruses (the case of most positive-strand RNA viruses) produce miRNAs. In this section, we summarize the currently available data regarding the origin and genomics of viral miRNAs.
EBV primarily infects B cells, and occasionally, T and epithelial cells. Following B cells infection, the viral DNA usually becomes latent and forms nuclear episomes, from which novel lytic cycles and particle production can be reinitiated ). EBV infection is usually benign but can occasionally promote the development of B-cell lymphomas, and several other tumors such as T-cell lymphomas and nasopharyngeal carcinoma ). Its association with human breast carcinoma remains controversial. Five miRNAs were initially found in EBV, clustered into two genomic regions. One cluster of three miRNAs, miR-BHRF1-1, -2 and -3 is proximal to the BHRF1 (Bam HI H Rightward Frame 1) open-reading frame (ORF), and one cluster of two miRNAs, miR-BART-1 and -2 is located within the BART (Bam HI A rightward transcript) gene (Pfeffer et al., 2004) . Two recent studies have now identified an additional set of 18 EBV miRNAs, 13 of which map to a B12 kb intronic region within the BART gene, which is deleted in the B95-8
Viruses, microRNAs and cancer S Pfeffer and O Voinnet strain used in the initial report Grundhoff et al., 2006) . Interestingly, all BART miRNAs accumulate specifically during latency, indicating that they might regulate this aspect of the infection. Cai et al. (2006) cloned small RNAs from another, distant member of the type 1 gammaherpesvirus genus, the rhesus lymphocryptovirus (rLCV) ( Table 1) . Remarkably, the 15 identified pre-miRNAs mapped to regions similar to those found in EBV, and eight mature miRNAs were conserved in sequence, suggesting important roles for those molecules in gammaherpesvirus infections. Nonetheless, with the exception of EBV and rLCV miRNAs, none of the known viral miRNAs exhibit sequence similarity between them or with host miRNAs. KSHV belongs to the gammaherpesvirinae subfamily (rhadinovirus genus) and is the primary etiological agent of Kaposi's sarcoma, an endothelial tumor developing in immunocompromised patients. KSHV is also associated with aggressive lymphomas such as body cavitybased lymphoma, pleural effusion lymphoma and multicentric Castleman's disease (Moore and Chang, 2001) . A total of 12 KSHV miRNAs have been identified in latently-infected B lymphoma cell lines (Cai et al., 2005; Pfeffer et al., 2005; Samols et al., 2005; Grundhoff et al., 2006) . Interestingly, they are all found within the same 5 kb cluster, which encodes the various isoforms of the protein Kaposin (K12), which induces cell transformation when overexpressed in vitro. One miRNA, miR-K12-10 is located within the sequence encoding Kaposin A, and another, miR-K12-12, is in the 3 0 untranslated region of this same transcript. The remaining 10 miRNAs are all within the intron of the large Kaposin primary transcript. A promoter driving expression of a primary transcript containing all 12 miRNAs has been mapped upstream of ORF73, encoding the latency-associated nuclear antigen LANA (Pearce et al., 2005) . However, as induction of the lytic cycle enhances expression of only the miRNA embedded within ORF K12 (Pfeffer et al., 2005) , an alternative promoter must drive expression of miR-K12-10 and K12-12. KSHV miRNAs have also been identified in infected endothelial cells indicating that their expression is not restricted to B cells (Samols et al., 2005) .
MHV68 is evolutionary related to the human gammaherpesviruses EBV and KSHV and is often used as an animal model for the biology of these viruses (Speck and Virgin, 1999) . All of the nine viral miRNAs cloned from a latently infected mouse B-lymphoma cell line mapped within a 6 kb region near the M1 ORF, and are located downstream of previously identified transfer RNA (tRNA) genes (Pfeffer et al., 2005) . The MHV68 miRNAs are expressed in a non-conventional manner from RNA Pol III-dependent transcripts containing the tRNA and one to two pre-miRNAs. This is in contrast with known cellular and other viral miRNAs, which are thought to be expressed from long, Pol II-dependent primary transcripts (Cai et al., 2004; Lee et al., 2004) .
The betaherpesvirus HCMV has the largest genome of all herpesviridae (230 kb), possibly encoding >250 ORFs. HCMV is associated with congenital diseases or post-transplant complications, but its link to cancer is not as evident as for gammaherpesviruses. For example, HCMV does not have transforming properties in vitro, although it may modify tumor cell biology through onco-modulation (see for review Soderberg-Naucler, 2006) . A total of nine HCMV-derived miRNAs were initially identified in lytically infected fibroblasts (Pfeffer et al., 2005) and two additional miRNAs were subsequently reported (Grey et al., 2005) . In contrast to KSHV and MHV68 miRNAs, HCMV miRNAs are spread across the genome: four are transcribed from strands opposite to described ORFs, six are in intergenic regions, and one is present in the intron of the antiapoptotic gene UL36 (Skaletskaya et al., 2001) .
Recently, one miRNA, miR-LAT, was identified in the alphaherpesvirus HSV1 (Gupta et al., 2006) . Its unusually high GC content and relatively short stem probably explain why it had escaped previous miRNA predictions made with this virus and its discovery suggests that there may be many more viral miRNAs than originally anticipated. miR-LAT was cloned from Viruses, microRNAs and cancer S Pfeffer and O Voinnet cells transfected with a plasmid expressing a 2.9 kb fragment of the viral genome, and was also detected in infected SY5Y cells. The miRNA is located within the HSV1 LAT (latency-associated transcript) gene, the only gene to be expressed during latent infection. Although HSV1 has not been linked to cancer, it will be discussed in this review because it provides the only example, so far, of a virus that encodes a miRNA with experimentally validated, host-encoded targets (see further sections of this review). Thirteen additional miRNA precursors have been computationally predicted in HSV1, one of which, located B450 bp upstream of the transcription start site of the LAT transcript, was found to produce a mature miRNA in infected cells (Cui et al., 2006) . Unlike the viruses described so far, SV40 is a member of the Polyomaviridae, a family of viruses with a circular dsDNA genome, B5 kb in length. Shortly after its discovery, SV40 was found to induce tumors in newborn hamsters or immunocompromised mice, and subsequent genetic analyses identified the large T antigen as being both necessary and sufficient for cell transformation (reviewed in (Ahuja et al., 2005) ). identified one miRNA, miR-S1, in the SV40 genome, encoded immediately 3 0 of the polyadenylation site of late transcripts. A similar genomic location had been predicted for miRNAs of the mouse polyomavirus , and the human polyomavirus BK (Pfeffer et al., 2005) , the later being tightly associated with carcinogenesis in human (Khalili et al., 2003; Tognon et al., 2003) . The SV40 miR-S1 sequence is perfectly complementary to the viral RNA strand of early viral transcripts that encode T antigens, and these transcripts indeed undergo sequence-specific cleavage by miR-S1 at late infection stages (detailed in the next section of this review).
The last virus to be discussed here is adenovirus, which, despite efficient transformation properties in rodent cells, has not been clearly associated with human cancers. This virus encodes a B160 nt noncoding RNA called VA1 that is expressed to extremely high levels in infected cells. Despite its structural features resembling those of miRNA precursors and its use of exportin 5 for transport to the cytoplasm (Lu and Cullen, 2004 ) (where it inhibits PKR activity) VA1 seems to be a poor Dicer substrate: only B1% of VA1 molecules are processed into B22 nt RNAs (Andersson et al., 2005; Sano et al., 2006) . Although these molecules can be incorporated into RISC to target artificial reporter genes (Aparicio et al., 2006; Sano et al., 2006) , their significance in adenovirus infection remains unclear.
Modes of action of viral miRNAs
Viral-encoded miRNAs can, in principle, function both in cis, by regulating accumulation of viral products, or in trans, by downregulating the expression of host transcripts (see Figure 1) . Although the function of most viral miRNAs remains at present uncertain, significant progresses have been made recently. SV40 miR-S1 was the first viral miRNA to which a cis-regulatory function was clearly ascribed . Because miR-S1 is encoded on the opposite strand of early T antigen transcripts, it is perfectly complementary to these transcripts. confirmed that miR-S1 does indeed promote cleavage of large T antigen transcripts during its expression in late infection stages (Figure 1, part 1) . However, this activity seems unessential for replication, because a virus with mutations in the miR-S1 gene accumulates to the same level as the wild-type virus. Rather, downregulation of large T antigen appears to lower the recognition and elimination of infected cells by cytotoxic T cells. Viral transcript cleavage in cis also appears to be a feature of the EBV-encoded miR-BART2, which targets the BALF5 mRNA encoding a subunit of the DNA polymerase (Pfeffer et al., 2004) , and is also likely to apply to several HCMV-encoded miRNAs that are complementary to the sequence of several viral ORFs (Pfeffer et al., 2005) . With both EBV and HCMV, miRNA-directed regulations may be critical to establish a balance of viral products required at specific phases of the infection, most notably during latency. Viral miRNAs could also regulate the expression of viral transcripts via translation inhibition through imperfect base pairing, but this situation has not yet been documented.
Owing to the current limitations in miRNA targets identification, it is only very recently that the first example of trans-regulatory effects exerted by a viral miRNA was reported. Fraser and co-workers identified two cellular targets of the HSV1 miR-LAT, encoded in the first exon of the LAT gene (Gupta et al., 2006) , which was previously shown to protect infected cells against apoptosis during latency. Remarkably, this property could be recapitulated in cells expressing a 2.9 kb fragment of LAT encompassing the miRNA. Those cells became protected against apoptosis induced by cisplatin, a process reversed by transfection of an antisense 2'O-methyl oligonucleotide complementary to miR-LAT. Accordingly, the antiapoptotic properties of HSV1 were lost in cells infected with a modified virus carrying a deletion in the miR-LAT gene. These observations helped the authors to narrow down their search for potential cellular targets to transforming growth factor (TGF)-b and SMAD3, which are functionally related in the TGF-b signaling pathway that inhibits cell proliferation and induces apoptosis ( Figure 1, part 2) . Both TGF-b and SMAD3 were indeed shown to be downregulated by miR-LAT (Gupta et al., 2006) . These results establish a clear role for miR-LAT during latent infection by a herpesvirus, and it is likely that many more examples of this kind will follow. Generally, one can anticipate that cellular targets of viral miRNAs will comprise regulators of adaptive and innate immune responses (including induction of apoptosis or the IFN responses) as well as signal-transduction components and, perhaps, regulators of cell proliferation.
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Possible roles of viral miRNAs in the development of cancer
Despite striking associations between most miRNAproducing viruses and cancer, one can only currently speculate about the potential influence that viral miRNAs might exert on oncogenesis. The most intuitive scenario relies on the possibility that some viral miRNAs could directly act as oncogenes. For instance, predicted targets of the EBV-encoded miR-BHRF1-1 include the tumor suppressor P53, in which mutations are found in 50% of all cancers (Soussi and Lozano, . On the other hand, miR-BART1, another EBVencoded miRNA that is coexpressed with miR-BHRF1-1 in latently infected B cell lymphomas, is predicted to target Bcl-2, which functions as an oncogene by blocking apoptotic cell death (Cory et al., 2003) . Assuming those target predictions are accurate, the coincident production, by the same virus, of miRNAs with possible opposing effects (pro-and antioncogenic) could reflect a tight control over cell proliferation signals by EBV, as has been shown in studies of oncogenic, endogenous miRNAs in human cells (see also the article by JT Mendell in this issue). Hence, c-Myc, a key regulator of cell proliferation, growth and apoptosis, directly binds to the promoter of the miR-17-5p/ miR-20a cluster and activates its transcription. The two miRNAs, in turn, repress expression of the E2F1 transcription factor, an additional target of c-Myc that promotes cell cycle progression. This example illustrates how c-Myc simultaneously activates E2F1 transcription and limits its translation, potentially resulting in finetuned regulation of cell proliferation (O'Donnell et al., 2005) . Viral miRNAs acting directly as oncogenes might be illustrated by the KSHV miR-K12-10 and miR-K12-12, both encoded within the transcript of the A isoform of Kaposin, which is known to mediate cellular transformation through loss of growth control and of surfacemediated inhibition (Kliche et al., 2001) . Because the major product of this region is an isoform of the protein (Kaposin B), which does not contain Kaposin A sequence (Sadler et al., 1999) , at least part of the transforming properties might be due to the expression of miR-K12-10 and miR-K12-12. Alternatively, as the Kaposin A transcript can be either translated or processed by Dicer, it could be that the miRNAs are indirectly implicated in cell tranformation by modulating accumulation of the active protein in infected cells. In this regard, it would be interesting to test whether Kaposin A and miR-K12-10 expressions are mutually exclusive.
The notion that viral miRNAs, like some of their cellular counterparts, could act as potential oncogenes makes the prediction and experimental confirmation of viral miRNA targets an urgent issue. This task is rendered difficult by the shear diversity of coexpressed viral miRNAs in infected cells, together with the fact that miRNAs in animal cells are predicted to control expression of many host genes owing to their mode of operation. Moreover, the actual target spectrum might be further broadened owing to specific post-transcriptional modifications affecting some viral miRNAs. For instance, miR-K12-10 is alternately edited at position 2 (Pfeffer et al., 2005) , which, in theory, could increase the number of putative targets, as this replaces an A with a G at a sensitive position within the miRNA seed. Note that editing of the Kaposin A transcript could also play a role in the efficacy of pre-miR-K12-10 processing, as has been described for cellular miRNAs (Yang et al., 2006) .
A second, non-exclusive scenario that might implicate some viral miRNAs into oncogenesis is through the facilitation of tumor progression in tissues that are already prone to develop cancer in the absence of an infection. This scenario might accommodate the observations that associations between some herpesviruses and cancer are sometimes more correlative rather than causal (Soderberg-Naucler, 2006) . Modulation, as opposed to direct induction, of cancer by miRNAs has been reported in the mouse B-cell lymphoma model in which the c-myc oncogene is driven by the immunoglobulin heavy-chain enhancer Em (Em-myc mice). It was found that enforced expression of the mir-17-92 cluster significantly accelerated lymphoma development in those mice (He et al., 2005) . Moreover, tumors derived from Em-myc hematopoietic stem cells that coexpressed a subset of the mir-17-92 cluster did not develop apoptosis, which otherwise prevailed in lymphoma from cells expressing Em-myc only. Interestingly, translocation of MYC into one of the immunoglobulin loci is commonly associated with EBV-induced Burkitt's lymphoma (Taub et al., 1982) , so that the possibility exists that some EBV-derived miRNAs could act in a manner similar to that of miR-17-92. Although HSV1 has not been linked directly to cancer, miR-LAT targeting of the proapoptotic factors SMAD3 and TGF-b (Gupta et al., 2006) , also supports the idea that miRNAs from herpesviridae may sometimes facilitate tumor progression when they are expressed in contexts that are already favorable to cancer.
Third, it is possible (if not likely) that most viral miRNAs will have an impact on cancer by facilitating the evasion, by oncogenic viruses, of innate and adaptive immune responses, thereby enabling longlasting infections that are presumably required to establish a ground for cancer development. In this scenario, viral miRNAs would not act as oncogenes, but as facilitators of the ingress and survival of a pathogen with oncogenic potentials. It is striking that most of the herpesviridae miRNAs characterized so far are strongly associated with latency, a key step of the infection that enables viruses to remain unnoticed by the immune system for years. Hence, EBV-associated cancers are sometimes manifested decades after the initial infection event ). Evidence supporting a role for viral miRNAs in avoiding inflammation comes from recent studies carried out with a naturally occurring variant of the mouse herpesvirus MHV68. This variant had a deletion within a portion of the genome encompassing all nine MHV68 miRNAs. Although it replicated as efficiently as the wild-type virus in vitro, its accumulation was significantly impaired in vivo because it triggered a much greater inflammatory response and was rapidly cleared from the organism by the immune system (Macrae et al., 2001) . Even though the deleted region contained four ORFs in addition to the miRNAs, this observation could indicate a role for viral miRNAs in immune system evasion and/ or control of latency. A similar role is seen with miR-S1 from SV40, which cleaves the transcript encoding large T antigen. Mutation of the miRNA does not impair viral replication, but rather results in a higher cytotoxic response against infected cells .
Finally, targeting by the HSV1 miR-LAT of the two proapoptotic genes TGF-b and SMAD-3 most likely helps the virus to maintain infected cells alive and, therefore, facilitates latency (Gupta et al., 2006) . Whether they act directly as oncogenes, or as some of the many factors contributing to tumorigenesis, a full appreciation of the effects of viral miRNAs on cancer awaits their characterization in authentic tumor contexts, as opposed to cultured cell lines, the material used so far in most, if not all, studies. This question is of prime importance because it is likely that the spectrum of virally expressed miRNAs will change depending on cell or tissue types, as is the case of cellular miRNAs. The nature of those variations might not only be qualitative (e.g. whether a viral pri-miRNA will or will not be expressed) but also quantitative (e.g. depending on the availability of enhancer elements in a given tissue). Recently, it was found that the KSHV-encoded miR-K12-5 was much more abundant in BC-1 than in BCBL-1 cells owing to the selection of a viral variant carrying a single-nucleotide polymorphism in the miR-K5 precursor stem-loop, which dramatically reduced its processing by Drosha (Gottwein et al., 2006) . This remarkable example further underscores the necessity to sample viral miRNA populations in vivo in order to establish potential links between viruses, miRNAs and cancer. This approach may be strengthened by the study of various stages of specific malignancies, combined with robust viral serological studies, both in patientderived tissues and in animal models.
Interactions between viruses and the host miRNA pathway that may have consequences for oncogenesis
The above examples were based on scenarios implicating viral-encoded miRNAs in cancer, either directly or indirectly. We discuss below the additional possibilities that interactions or perturbation of host miRNA repertoires by viruses might influence cancer development. Hence, many vertebrate miRNAs appear to be critically implicated in cell differentiation and/or maintenance of differentiated states, and, accordingly, deregulation of cellular miRNA profiles is often associated with cancer (see other contributions in this issue). Moreover, a limited body of evidence indicates that miRNA genes have complex transcriptional patterns and can respond to various stimuli, including biotic stress (Johnson et al., 2003; Yeung et al., 2005; Navarro et al., 2006) . For instance, a recent micro-array study in HIV-1-infected Hela cells revealed a general downregulation (by at least two fold) of nearly 40% of a 312 miRNA gene set (Yeung et al., 2005) . It is conceivable, therefore, that some viruses might trigger changes in miRNA transcription profiles or stability, and that the resulting, modified miRNA repertoire might favor cancer development (Figure 1,  part 3 ). This may be particularly relevant if the altered miRNA gene set includes host miRNAs with oncogenic properties.
A second possibility is that the host miRNA machinery might be overwhelmed by the shear amount of miRNAs or miRNA-like molecules produced by some viruses, such that miRNA processing-, export-or effector-complexes might be out-competed or diverted away from their normal cellular functions, including cell fate maintenance (Figure 1, part 4) . For instance, the VA1 non-coding RNA from adenovirus accumulates up to 10 8 copies per cell and, despite its poor processing by Dicer (estimated at 1%), the expected figure of 10 6 small RNA molecules accumulating in infected cells is probably higher than the sum of all expressed cellular miRNAs (Andersson et al., 2005; Sano et al., 2006) . On a lower scale, KSHV miRNAs represented up to onefourth of all cloned miRNAs in the latently infected BCBL1 cell line (Pfeffer et al., 2005) . The severe biological consequences of overriding the host miRNA machinery was exemplified recently in adult mice sustaining high level, prolonged short-hairpin (sh)RNA delivery in the liver (Grimm et al., 2006) . Nearly 70% of the constructs caused liver injuries (46% of which ultimately caused death) that were ascribed, at least partly, to saturation of the pre-miRNA cytoplasmic export by exportin 5, which is also a known output of VA1 accumulation. In this particular example, the extent of the perturbation of miRNA-directed functions was such that it caused cell death, but it is conceivable that more moderate effects might promote cancer through loss of cell fate. dsRNA-binding proteins, which are commonly deployed by mammalian viruses to antagonize innate immune responses (notably the IFN response) might also interfere with miRNA processing or functions (Figure 1, part 5 ). For instance, the influenza NS1 protein binds siRNAs (Bucher et al., 2004) , and possibly miR/miR* duplexes and there are multiple examples in plants, in which dsRNA-binding proteins, including VSRs, perturb miRNA-directed functions (Mallory et al., 2002; Chapman et al., 2004; Dunoyer et al., 2004) . More generally, virus infections might alter the transcript or protein levels of cellular factors involved in miRNA biogenesis/action, although, surprisingly, this has not been investigated so far.
Perhaps a more intriguing scenario linking miRNAs, cancer and viruses is the possibility that the altered cellular miRNA repertoires found in cancerous tissues might influence their permissivity to specific viruses. This hypothesis is based on at least two examples in which individual cellular miRNAs were shown to engage in sequence-specific interactions with viruses (Jopling et al., 2005; Lecellier et al., 2005) . In one example, the liver-specific miR-122 was shown to favor the replication of HCV, possibly contributing to the general prevalence of HCV in hepatic cells (Jopling et al., 2005) . Transposed into the context of cancer, those results suggest that tumor-specific changes in miRNA expression profiles could explain why a given virus and a given cancer type are often found in association regardless of causal relationships. One could expect, nonetheless, that infected cells might endure complications that would not be found in similar, non-infected cancerous tissues.

Conclusion
The rather speculative nature of this review is probably a reflection of the fact that we are just beginning to appreciate the intricate relations between viruses and RNA silencing pathways in vertebrates and, more specifically, in mammals. Nonetheless, the discovery of virus-encoded miRNAs is likely to profoundly change our views of host-virus interactions and of their pathological outcomes. In addition, we presented here various hints as to how viruses can interfere with miRNA biogenesis and function, thereby establishing an environment that may ultimately lead an infected cell to become cancerous. We would finally like to conclude this review by putting forward a somewhat provocative idea that, we believe, might deserve careful attention: as much as perturbation of cellular miRNA profiles might favor cancer development, the mis-regulation rather than mere expression of viral-encoded miRNA genes could be at the core of their potential link to cancer.
